Sign In  |  Register  |  About Burlingame  |  Contact Us

Burlingame, CA
September 01, 2020 10:18am
7-Day Forecast | Traffic
  • Search Hotels in Burlingame

  • ROOMS:

A Review Of Changes In Institutional Ownership: $BCDA $POAI $ABIO

*If You Own BCDA, POAI, ABIO Then Click Here to Join Our Community Of Traders

The Market Signal was created as a platform to help investors, if you own (NASDAQ:BCDA), (NASDAQ:POAI) or (NASDAQ:ABIO) and want to join the fastest growing community of investors on the web then sign up to the link below. Members get free access to the best investment tools in the world. Start trading like a pro today. This is a limited time offer so click the link below NOW.

(Click link above or copy, paste and hit enter in your browser for your report)

BioCardia's efforts to handle chronic myocardial ischemia (CMI) Free-Report/BCDA

(Click link above or copy, paste and hit enter in your browser for your report)

BioCardia Inc (NASDAQ:BCDA) institutional ownership over the period of 3-months changed by 141.85%.

The trial set to study CardiAMP(R) cell therapy which happens to be an investigational product for handling chronic myocardial ischemia (CMI), has been activated. That is according to the manufacturer BioCardia(R), Inc. The company has already made its initial visit to the first trial site

The CardiAMP CMI Trial is set to help the company discover a lot about the CardiAMP cell therapy. The therapy is designed to work on the body's natural healing process. Proper functioning of the therapy could mean the effective treatment of the acute refractory angina.

The above condition according to sources is said to affect a large portion of the total United States population. Precisely, the figures range between 600,000 and 1,800,000 patients.

This critical condition is known to cause massive impairments in the quality of lives that the affected persons lead. The condition has topped the list when it comes to those conditions regarded as being a huge burden to the health care system. That is looking at the significant amount of resources that are usually channeled here. The psychological distress has also been mentioned as a major cause for alarm.

The FDA has already given its approval to the study and it is set to enroll about 343 patients. There are also reports that the studies will be conducted in almost 40 centers. The central objective will be to identify both the efficacy and the safety of the therapy to the various consumers.

This is being seen by many as turnaround time for patients struggling with refractory angina CMI and pectoris. The FDA has given out its word, specifically outlining the qualification of the pivotal trial. According to the body, it has the required primary data necessary to back up the CardiAMP cell therapy market registration. The unmet clinical need continues to plunge a lot of people in a state of utter frustration, but that might change soon if everything works out.

Predictive Oncology to add more board members Free-Report/POAI

(Click link above or copy, paste and hit enter in your browser for your report)

Predictive Oncology Inc (NASDAQ:POAI) institutional ownership over the period of 3-months changed by 206.66%.

To boost the company's board of directors Predictive Oncology made new appointments. The new members will start acting out their roles with immediate effect. Here are the new members:-

  • Greg St. Clair
  • Nancy Chung-Welch, Ph.D.
  • Charles L. Nuzum, CPA

Overall, the board has a total of seven members. The plans underway are for each of the board members to function as independent directors. All of them will have to conform, to the Nasdaq Corporate Governance rules.

Predictive Oncology (NASDAQ: POAI) recently spoke about the purchase of biomedical analytics and computational biology company known as Quantitative Medicine LLC ("QM"). That was a major achievement that was settled at about $1.8 million in the form of an all-stock transaction.

Changes in the institutional ownership of ArcaBiopharma Free-Report/ABIO

(Click link above or copy, paste and hit enter in your browser for your report)
ArcaBiopharmaInc(NASDAQ:ABIO)institutional ownership over the period of 3-months changed by 172.67%.

AB201 (rNAPc2) - a minute integrated protein manufactured with the aim of having it serve as a potential remedy for the RNA virus associated disease. Initially, it was meant to target COVID-19.

  • Plan to develop AB201 which will play a massive role in treating patients struggling with severe COVID-19.
  • Establishing clinical collaboration with the Academic Research Organization at the University of Colorado. That is together with the Colorado Prevention Center.
  • The company's intended move to file for a new investigational Drug (IND) application for AB201.This product is anticipated to help with the treatment of COVID-19. The filing was done made in the third quarter of this year with the U.S. Food and Drug Administration (FDA).

ARCA looking forward to starting the AB201 Phase 2 clinical testing set to take place this year in the fourth quarter.

Cash and cash equivalents were $11.0 million as of June 30, 2020, compared to $8.4 million as of December 31, 2019. Cash includes net proceeds of $24.1 million raised in July from sales of its common stock. Total operating expenses 2Q 2020 were $1.3 million compared to $1.5 million for 2Q 2019. Net loss for 2Q 2020 was $1.3 million, or $0.73 per basic and diluted share, compared to $1.4 million, or $1.14 per basic and diluted share, for 2Q 2019.

The Company will need to raise additional capital, and/or complete a partnership or other possible strategic transaction, to fund future operations and develop AB201 and Gencaro or any other product candidates.

Please email or contact us for any edits or errors relating to this stock market news.

If you would like information on using our press release distribution service aimed at helping investors with the best stocks to buy and how to create your own stock portfolio. We cover the US Stock Market, Canadian Stock Market, the Australian Stock Market, and other Stock Market news.

We will get back to you within 24 hours.


comtex tracking


Is there a problem with this press release? Contact the source provider Comtex at

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Copyright © 2010-2020 & California Media Partners, LLC. All rights reserved.